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Transcriptome and proteome analyses in psychiatric dis-
eases have furthered the understanding of pathogenesis on
a molecular level. However, most of the potential bio-
marker candidates have not been validated in peripheral
ﬂuids such as blood and cerebrospinal ﬂuid (CSF). In
schizophrenia, there is a need for biomarkers allowing
early diagnosis and prediction of outcome as well as
development of treatment options based on neurobiological
processes. However, the management and safety of lumbar
puncture in schizophrenia patients is under discussion.
Kranaster et al. [1] report here for the ﬁrst time an evalu-
ation of clinical use and safety of CSF diagnosis in 155
patients with ﬁrst-episode schizophrenia. This study may
encourage future investigations of CSF biomarkers in the
disease.
A further marker of disturbed brain development in
schizophrenia is the gyriﬁcation index of the brain, which
is determined during neurodevelopment and may be under
genetic control. In a study in monozygotic and twins and
unrelated siblings, Hasan et al. [2] found no effects of
genetic background on the gyriﬁcation index in several
brain regions, suggesting a stronger inﬂuence of environ-
mental factors like intrauterine conditions and early post-
natal development on this morphological feature.
Other structural abnormalities such as ventricular
enlargements are among the most consistent ﬁndings in
schizophrenia. In a combined structural MRI and DTI
study, Horga et al. [3] report that ventricular enlargement is
globally interrelated with gray matter volume deﬁcits but
not with volume loss in the immediately adjacent caudate,
putamen, or internal capsule. Oligodendrocytes play a
major role in nerve cell propagation and myelination of
axons connecting brain regions. Effects of antipsychotic
medication on oligodendrocyte degeneration have been
investigated by Steiner et al. [4], who found cell protective
effects of haloperidol and clozapine in a serum and glucose
deprivation model, suggesting that previously reported
decreases in oligodendrocyte numbers in schizophrenia are
rather disease related than caused by antipsychotic
medication.
Degner et al. [5] deal with another aspect of atypical
antipsychotic treatment, namely EEG alterations in
patients under olanzapine treatment, which have been
commonly observed and found to be dependent on dos-
age. Pharmacological treatment in major psychoses should
consider medical and psychopathological comorbidities.
Altamura et al. [6] give an actual overview on this topic.
An important treatment outcome in schizophrenia is the
subjective quality of life and psychosocial functioning.
They were measured by different rating scales and
showed that greater symptom severity and worse insight
were associated with worse functioning and stress further
investigations on identifying treatment targets to improve
social functioning in schizophrenia [7]. In a Brazilian
catchment area, a psychosis continuum has been detected
in a sample of 1,464 adults in order to identify psychotic
symptoms [8]. Different risk factors have been identiﬁed
inﬂuencing the manifestation of psychotic symptoms.
Altogether, this issue of EAPCN gives a broad overview
on neurobiological, treatment-related and psychosocial
aspects of psychosis.
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